Literature DB >> 17028156

Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products.

Kwang Seok Ahn1, Gautam Sethi, Bharat B Aggarwal.   

Abstract

Identifying the active chemical ingredients of ancient medicines and the molecular targets of those ingredients is an attractive therapeutic objective. Embelin, identified primarily from the Embelia ribes plant, is one such compound shown to exhibit chemopreventive, anti-inflammatory, and apoptotic activities through an unknown mechanism. Because nuclear factor-kappaB (NF-kappaB) regulates several genes associated with inflammation, proliferation, carcinogenesis, and apoptosis, we postulated that embelin might mediate its activity through modulation of NF-kappaB activation. We found that embelin inhibited tumor necrosis factor (TNF) alpha-induced NF-kappaB activation. Both inducible and constitutive NF-kappaB activation were abrogated by embelin. In addition, NF-kappaB activated by diverse stimuli such as interleukin-1beta, lipopolysaccharide, phorbol myristate acetate, okadaic acid, hydrogen peroxide, and cigarette smoke condensate also was suppressed. We found that embelin inhibited sequentially the TNFalpha-induced activation of the inhibitory subunit of NF-kappaBalpha (IkappaBalpha) kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, and p65 phosphorylation and nuclear translocation. Embelin also suppressed NF-kappaB-dependent reporter gene transcription induced by TNFalpha, TNF receptor-1 (TNFR1), TNFR1-associated death domain protein, TNFR-associated factor-2, NF-kappaB-inducing kinase, and IkappaBalpha kinase but not by p65. Furthermore, we found that embelin down-regulated gene products involved in cell survival, proliferation, invasion, and metastasis of the tumor. This down-regulation was associated with enhanced apoptosis by cytokine and chemotherapeutic agents. Together, our results indicate that embelin is a novel NF-kappaB blocker and potential suppressor of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028156     DOI: 10.1124/mol.106.028787

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  54 in total

1.  PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel.

Authors:  Yixian Huang; Jianqin Lu; Xiang Gao; Jiang Li; Wenchen Zhao; Ming Sun; Donna Beer Stolz; Raman Venkataramanan; Lisa Cencia Rohan; Song Li
Journal:  Bioconjug Chem       Date:  2012-06-20       Impact factor: 4.774

2.  Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Jeffrey DeSano; Ezra Burstein; Mary Davis; Kenneth Pienta; Theodore Lawrence; Liang Xu
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Authors:  Aldo M Roccaro; Antonio Sacco; Brian Thompson; Xavier Leleu; Abdel Kareem Azab; Feda Azab; Judith Runnels; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Charles P Lin; Domenico Ribatti; Barrett J Rollins; Thomas E Witzig; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

4.  Anticancer cardamonin analogs suppress the activation of NF-kappaB pathway in lung cancer cells.

Authors:  Weiyan He; Yu Jiang; Xuebing Zhang; Yue Zhang; Honglei Ji; Nan Zhang
Journal:  Mol Cell Biochem       Date:  2014-01-04       Impact factor: 3.396

5.  Proteins from an unevolved library of de novo designed sequences bind a range of small molecules.

Authors:  Izhack Cherny; Maria Korolev; Angela N Koehler; Michael H Hecht
Journal:  ACS Synth Biol       Date:  2012-04-02       Impact factor: 5.110

6.  Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells.

Authors:  Mouad Edderkaoui; Aurelia Lugea; Hongxiang Hui; Guido Eibl; Qing-Yi Lu; Aune Moro; Xuyang Lu; Gang Li; Vay-Liang Go; Stephen J Pandol
Journal:  Nutr Cancer       Date:  2013-10-15       Impact factor: 2.900

7.  Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer.

Authors:  Yao Dai; Jeffrey Desano; Yang Qu; Wenhua Tang; Yang Meng; Theodore S Lawrence; Liang Xu
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

8.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

9.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

Authors:  Yao Dai; Theodore S Lawrence; Liang Xu
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

10.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Yongming Li; Jiqin Lian; Theodore S Lawrence; Liang Xu
Journal:  BMC Cancer       Date:  2009-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.